Search Results

The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.

364 Results Found

News
Public

Chair File: Leadership Dialogue — The Importance of the 340B Program with Aimee Kuhlman of the AHA and Paulette Davidson of Monument Health

AHA Board Chair Tina Freese Decker talks with AHA VP Aimee Kuhlman and Monument Health CEO Paulette Davidson about the benefits of the 340B program.
Content
Public

The Future of 340B: What Hospitals and Rural Communities Need to Know

In this Leadership Dialogue conversation, Tina Freese Decker, president and CEO of Corewell Health and 2025 AHA board chair, joins Aimee Kuhlman, vice president of advocacy grassroots and government relations at the AHA, and Paulette Davidson, president and CEO of Monument Health, to unpack what’s at stake.
Fact Sheets
Public

Fact Sheet: The 340B Drug Pricing Program

Learn what the HHS 340B Drug Pricing Program is and what 340B hospitals are. The program allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients by providing 340B drug pricing discounts and expand health services to the patients and communities they serve.
340B Advocacy Alliance Bulletin
Member

AHA 340B Advocacy Alliance

A Bloomberg article published today (linked here and text below) discusses how the Department of Health and Human Services plans to “survey safety-net hospitals on the amount they pay for prescription drugs, following up on an effort to reduce the hospitals’ Medicare drug reimbursement during the president’s first term.”

Amicus Briefs

The AHA weighs in on a number of issues of importance to hospitals and health systems, as well as the patients they care for, as they come before the court. Below are our most recent friend-of-the-court briefs.
News
Public

Chair File: Protecting 340B and Access to Care

For more than 30 years, thanks to bipartisan congressional support, the 340B program has helped eligible hospitals stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients and expand health services to the communities they serve.
Fact Sheets
Public

Fact Sheet: 340B Drug Pricing Program: Fact vs Fiction

For nearly 30 years, the 340B Drug Pricing Program has provided financial help to safety-net hospitals to manage rising prescription drug costs. Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to qualifying health care organizations that care for many uninsured and low-income patients.
News

HRSA approves 8 drug company plans for participation in 340B Rebate Model Pilot Program

The Health Resources and Services Administration posted on its website that it had approved eight drug company plans
340B Advocacy Alliance Bulletin
Member

AHA 340B Advocacy Alliance Bulletin - October 30, 2025

The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model Pilot Program with a start date of Jan. 1, 2026.
340B Advocacy Alliance Bulletin
Member

340B Advocacy Alliance Bulletin - October 23, 2025

The Senate Committee on Health, Education, Labor and Pensions today held a hearing discussing the 340B Drug Pricing Program and its growth and impacts on patients.